Oxford Biomedica bags Novartis leukaemia deal

Pharmaceutical giant Novartis has signed up biotech firm Oxford Biomedica to provide its gene delivery technology for a programme targeting various forms of leukaemia.

Pharmaceutical giant Novartis has signed up biotech firm Oxford Biomedica to provide its gene delivery technology for a programme targeting various forms of leukaemia.

The deal, which is worth between £2.5m and £4.0m to Oxford Biomedica over the next 12 months, will see the Oxford company's LentiVector gene delivery technology manufacture clinical grade genetic material for Novartis's CTL019 clinical development programme.

CTL019 is the lead project in a leukaemia-focused collaboration between the Swiss 'big pharma' player and the University of Pennsylvania.

CTL019 uses a gene delivery system called a lentiviral vector to genetically modify a patient's immune cells before they are re-infused into patients.

According to Edison Investment Research, such 'ex vivo' techniques "are typically difficult to scale-up easily and the deal helps validate Oxford BioMedica's viral vector production expertise".

"Additionally, it also highlights that gene therapy has the potential to dramatically alter life-threatening and severely debilitating disease outcomes."

Oxford BioMedica's Chief Executive Officer John Dawson said: "The strategic investment in our specialist manufacturing capabilities is a pivotal step towards building a financially self-sustaining business and this collaboration is an example of how we can commercialise our expertise."

Edison notes that the Novartis payments should mean that the company, which had net cash at end-2012 of £14.1m and is estimated to be burning cash at around £1.0m per month, has enough cash to reach the second quarter of 2014.

Shares in Oxford Biomedica were up 15% at 1.9p by 09:49 on the morning of the announcement.

OH

Recommended

The MoneyWeek Podcast: picking stocks is fun, but you need to do your homework
Investment strategy

The MoneyWeek Podcast: picking stocks is fun, but you need to do your homework

John Stepek talks to Steve Clapham, investor, analyst and author of The Smart Money Method, about the dangers in picking individual stocks and why you…
8 Apr 2021
BP looks set to return more money to shareholders as it beats expectations
Energy stocks

BP looks set to return more money to shareholders as it beats expectations

Oil major BP is to embark on a share buyback programme after significantly reducing its debts. Saloni Sardana looks at what it means for your portfoli…
6 Apr 2021
Deliveroo has hit the market – but it’s not getting the warmest welcome
UK stockmarkets

Deliveroo has hit the market – but it’s not getting the warmest welcome

Food delivery company Deliveroo made its debut on the stockmarket this morning. But with the share price sliding by 30% straight away, it’s not made t…
31 Mar 2021
Three stocks to buy now that will come back stronger after Covid-19
Share tips

Three stocks to buy now that will come back stronger after Covid-19

Professional investor Ed Wielechowski of Odyssean Capital, chooses three compelling stocks that should thrive in a post-pandemic world.
29 Mar 2021

Most Popular

The bitcoin bubble will burst: here’s how to play it
Bitcoin

The bitcoin bubble will burst: here’s how to play it

The cryptocurrency’s price has soared far beyond its fundamentals, says Matthew Partridge. Here, he looks at how to short bitcoin.
12 Apr 2021
What does the Coinbase listing mean for bitcoin and other cryptocurrencies?
Bitcoin

What does the Coinbase listing mean for bitcoin and other cryptocurrencies?

As the bitcoin price hit new highs, the world's biggest cryptocurrency exchange, Coinbase, listed on the stockmarket. John Stepek looks at what that m…
15 Apr 2021
Properties for sale for around £400,000
Houses for sale

Properties for sale for around £400,000

From a converted church in Banffshire with views towards the Cairngorms National Park, to a period property in the Georgian market town of Beverley, e…
2 Apr 2021